Abstract
Mutant KRAS has so far proven to be an undruggable target for lung adenocarcinoma and a widely held assumption is that KRAS mutations confer independence from upstream signalling. Two groups have now independently shown this might not be the case and suggest pan-ERBB inhibitors could be used to treat patients with KRAS-driven lung cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
